TSC, which is being developed by Diffusion Pharmaceuticals, has been shown to enhance the oxygenation of hypoxic tumor tissue [7] and belongs to a subclass of oxygen diffusion-enhancing compounds known as bipolar trans carotenoid salts.[2] Diffusion Pharmaceuticals is currently investigating the use of trans sodium crocetinate in the treatment of COVID-19, acute stroke, and solid cancerous tumors.[8]